Report Overview

The European Diabetes drugs market size stood at USD 12.89 billion in 2020 and is expected to rise to USD 20.06 billion by the end of 2028 exhibiting a CAGR of approximately 5.68% during the forecast period.

Diabetes severely compromises the quality of life in people by harbouring numerous complications that hamper daily activities. The healthcare system of Sweden is putting up a massive fight against one of the most significant emergencies in terms of global health. The direct and indirect costs of Diabetes in Sweden are high. The societal cost has been estimated to be SEK 18 billion in 2020 and is expected to reach SEK 21 billion in 2030. The reason is the direct association with the cost required for medical management and the indirect association with the monetary loss due to loss of productivity, early and premature mortality and decline of the countrys Gross Domestic Product.



Market Drivers

Diabetes disease market is driven by the increasing prevalence of Diabetes in the country. The trend of rising geriatric population with Diabetes in Sweden adds to the problem, which demands for viable treatment options.

Diabetes disease market is driven by increased investment in the area of research and development in order to make use of newer technology to provide simple alternatives to otherwise complex treatment protocols. This warrants lifestyle compatible treatment options.

The market is also driven by increasing Government funding for managing the disease. Sweden tends to have increased awareness about the disease which often promotes people to take timely care.